Granite Point Capital Management, L.P. Incyte Corp Transaction History

Granite Point Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 13, 2018	SELL	$60.85 - $83.98 $1.22 Million - $1.68 Million	-20,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $1.66 Million - $2.02 Million	20,000 New	20,000 $1.67 Million
Q4 2017 Feb 08, 2018	SELL	$93.56 - $116.6 $1.68 Million - $2.1 Million	-18,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $600,325 - $760,485	5,500 Added 44.0%	18,000 $2.1 Million
Q2 2017 Aug 10, 2017	BUY	N/A	12,500	12,500 $1.57 Million

619

215M

366K

445K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $14.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.